FP330 APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR …
METHODS: In the phase II clinical studies, ASSERT & ASSURE, high risk CVD patients were
treated with 100 mg bid apabetalone vs. placebo. In a phase I renal impairment study, CS …
treated with 100 mg bid apabetalone vs. placebo. In a phase I renal impairment study, CS …
FP330 APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR …
K Kalantar-Zadeh, C Zoccali, S Beddhu… - Nephrology Dialysis …, 2019 - academic.oup.com
METHODS: The expression of SNCA in the kidney was investigated in C57BL/6J mice
subjected to unilateral ureteral obstruction (UUO) and in patients with chronic kidney …
subjected to unilateral ureteral obstruction (UUO) and in patients with chronic kidney …
FP330APABETALONE, A SELECTIVE BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITOR, REDUCES SERUM FGF23 IN CARDIOVASCULAR …
K Kalantar-Zadeh, C Zoccali, S Beddhu… - Nephrology Dialysis …, 2019 - escholarship.org
INTRODUCTION: Fibroblast growth factor-23 (FGF23) is an osteocytic phosphaturic
hormone known to increase renal phosphorus excretion and reduce calcitriol synthesis via …
hormone known to increase renal phosphorus excretion and reduce calcitriol synthesis via …
[PDF][PDF] Apabetalone, A Selective Bromodomain And Extraterminal (BET) Protein Inhibitor, Reduces Serum FGF23 In Cardiovascular Disease and Chronic Kidney …
K Kalantar-Zadeh, C Zoccali, S Beddhu… - resverlogix.com
Abstract INTRODUCTION AND AIMS: Fibroblast growth factor-23 (FGF23) is an osteocytic
phosphaturic hormone known to increase renal phosphorus excretion and reduce calcitriol …
phosphaturic hormone known to increase renal phosphorus excretion and reduce calcitriol …